Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack T Stapleton

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2020
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial DiseaseGetahun Abate, Jack T Stapleton, Nadine Rouphael, et al.
Journal of Virology|November 3, 2017
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal ChallengeDelphine C Malherbe, Jason Mendy, Lo Vang, et al.
Lancet (London, England)|September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyS Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 22, 2020
Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial DiseaseGetahun Abate, Jack T Stapleton, Nadine Rouphael, et al.
Journal of Virology|November 3, 2017
Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal ChallengeDelphine C Malherbe, Jason Mendy, Lo Vang, et al.
Lancet (London, England)|September 6, 2014
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyS Rachel Skinner, Anne Szarewski, Barbara Romanowski, et al.
Vaccine|January 5, 2025
Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimensHana M El Sahly, Evan J Anderson, Lisa A Jackson, et al.
Lancet (London, England)|September 10, 2017
Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trialWarner K Huh, Elmar A Joura, Anna R Giuliano, et al.
The Lancet. Infectious Diseases|July 5, 2016
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE studyCosette M Wheeler, S Rachel Skinner, M Rowena Del Rosario-Raymundo, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 15